Post-Neoadjuvant Breast Pathology: Current Reporting Standards and Biomarker Testing Controversies
This guide for pathologists covers the reporting of post-neoadjuvant breast carcinoma specimens, from pretreatment biopsy through surgical specimen evaluation, including staging systems, prognostic biomarker retesting, and clinical implications of residual disease assessment. It addresses practical questions about representative sampling and when to retest ER, PR, HER2, and Ki-67 on post-treatment tissue. Essential reading for surgical pathology labs handling increasing volumes of neoadjuvant-treated breast cancer specimens.
The original study
Current concepts and controversies in post-neoadjuvant breast pathology.
- Authors
- Bean GR, Calhoun BC
- Journal
- Human pathology
- Type
- Journal Article, Review
- PMID
- 40473043
Original abstract
This review aims to be a helpful guide for pathologists in summarizing the current concepts and controversies in the reporting of post-neoadjuvant breast carcinoma specimens. It is structured to chronologically detail the relevant points from the initial diagnosis in the pretreatment biopsy to the gross and microscopic evaluation of the posttreatment surgical specimen, with pertinent digressions related to imaging, representative sampling, staging systems, prognostic biomarker testing, and clinical implications of reporting residual disease.